+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Pain Market Analysis by Disease Indication, by Drug Type, and by Region - Global Forecast to 2029

  • PDF Icon

    Report

  • 132 Pages
  • September 2022
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5653934
The cancer pain market size is estimated to be USD 6,599.12 million in 2021 and is expected to witness a CAGR of 5.71% during the forecast period 2022-2029. The ageing population, rising cancer prevalence, rising healthcare costs, and rising R&D spending by various healthcare businesses are projected to drive the market growth in near future. However, side effects like medication tolerance, drug dependence, urine retention, sleep problems, cognitive impairment, and others are expected to restrain the market growth.

By Disease Indication

Based on disease indication, the market is categorized into colorectal cancer, blood cancer, lung cancer, breast cancer, prostate cancer, and others. In 2021, the lung cancer accounted for the highest revenue share due to rising lung cancer prevalence, an increase in the incidence of pain related to lung cancer, and the accessibility of efficient cancer pain analgesics for the treatment of lung cancer.

By Drug Type

On the basis of drug type, the market is categorized into non-opioids, opioids, nerve blockers. In the global market, the opioids segment accounted for the largest revenue share in 2021 owing to increase in the incidence of severe cancer pain, the expansion in the use of opioids to treat cancer pain, and the significant availability of pipeline drugs.

Regional Markets In 2021, North America region accounted for the highest revenue in the cancer pain market and is expected to maintain its dominance during the forecast period. This is attributed to rising cancer prevalence, technological advancements in the healthcare industry, the accessibility of pain therapeutics, and the availability of top-notch chemotherapy treatment options. However, the Asia-Pacific region is anticipated to register the substantial CAGR because of the region's rapid increase in cancer prevalence, growing senior population, and growing awareness of the need of early cancer detection.

Competitor Insights

Some of the key players operating in the cancer pain market are
Mundipharma International Limited, Biodelivery Sciences International, Inc., Aoxing Pharmaceutical Company, Inc., Ck Life Sciences (Wex Pharmaceuticals)., Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo Ab, Pfizer Inc., Grünenthal Pharma Gmbh & Co. Kg, and Teva Pharmaceutical Industries Limited.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including disease indication and drug type from 2021 to 2029.

Segmentation: Cancer Pain Market Report 2021-2029

Disease Indication (Revenue, USD Million)

  • Colorectal Cancer
  • Blood Cancer
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others

Drug Type (Revenue, USD Million)

  • Non-Opioids
  • Opioids
  • Nerve Blockers

By Region (Revenue, USD Million)

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
1.4.1. Research Models
1.4.1.1. Bottom-up Approach
1.4.1.2. Top-down Approach
1.4.1.3. Data Triangulation
1.4.2. Data Procurement
1.4.2.1. Internal Database
1.4.2.2. Secondary Research
1.4.2.3. Purchased Database
1.4.2.4. Primary Research
1.4.3. Data Analysis
1.4.3.1. Data Validation
1.4.3.2. Market Size Estimation
1.4.3.3. Market Forecast Model
1.4.4. Quality Assessment
2. Introduction: Cancer Pain
3. Executive Summary
3.1. Global Market Scenario
3.2. Segment Market Scenario
3.3. Geographic Market Scenario
3.4. COVID-19 Impact
3.5. Competitive Landscape
4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.1.5. Driver 5
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.2.4. Restraint 4
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.3.4. Opportunity 4
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.4.4. Trend 4
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3
4.5.4. Challenge 4
5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. Value Chain Analysis
5.4. SWOT Analysis
5.5. Benchmark
6. COVID-19 Impact Analysis: Cancer Pain Market
6.1. COVID-19: Overview
6.2. COVID-19 Impact on the Global Market
6.3. COVID-19 Impact on the Regional Markets
7. Market Analysis by Disease Indication
7.1. Colorectal Cancer
7.1.1. Colorectal Cancer Market Forecast, 2021-2029 (USD Million)
7.2. Blood Cancer
7.2.1. Blood Cancer Market Forecast, 2021-2029 (USD Million)
7.3. Lung Cancer
7.3.1. Lung Cancer Market Forecast, 2021-2029 (USD Million)
7.4. Breast Cancer
7.4.1. Breast Cancer Market Forecast, 2021-2029 (USD Million)
7.5. Prostate Cancer
7.5.1. Prostate Cancer Market Forecast, 2021-2029 (USD Million)
7.6. Others
7.6.1. Others Market Forecast, 2021-2029 (USD Million)
8. Market Analysis by Drug Type
8.1. Non-Opioids
8.1.1. Non-Opioids Market Forecast, 2021-2029 (USD Million)
8.2. Opioids
8.2.1. Opioids Market Forecast, 2021-2029 (USD Million)
8.3. Nerve Blockers
8.3.1. Nerve Blockers Market Forecast, 2021-2029 (USD Million)
9. Regional Market Analysis
9.1. Regional Market Trends
9.2. Regional Market: Comparative Analysis
10. North America Cancer Pain Market
10.1. North America Cancer Pain Market
10.1.1. North America Market Size and Forecast, 2021-2029 (USD Million)
10.1.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
10.1.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
10.2. U. S. Cancer Pain Market
10.2.1. U. S. Market Size and Forecast, 2021-2029 (USD Million)
10.2.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
10.2.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
10.3. Canada Cancer Pain Market
10.3.1. Canada Market Size and Forecast, 2021-2029 (USD Million)
10.3.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
10.3.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
11. Europe Cancer Pain Market
11.1. Europe Cancer Pain Market
11.1.1. Europe Market Size and Forecast, 2021-2029 (USD Million)
11.1.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
11.1.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
11.2. Germany Cancer Pain Market
11.2.1. Germany Market Size and Forecast, 2021-2029 (USD Million)
11.2.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
11.2.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
11.3. UK Cancer Pain Market
11.3.1. UK Market Size and Forecast, 2021-2029 (USD Million)
11.3.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
11.3.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
11.4. France Cancer Pain Market
11.4.1. France Market Size and Forecast, 2021-2029 (USD Million)
11.4.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
11.4.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
11.5. Spain Cancer Pain Market
11.5.1. Spain Market Size and Forecast, 2021-2029 (USD Million)
11.5.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
11.5.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
11.6. Italy Cancer Pain Market
11.6.1. Italy Market Size and Forecast, 2021-2029 (USD Million)
11.6.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
11.6.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
11.7. Rest of Europe Cancer Pain Market
11.7.1. Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
11.7.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
11.7.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
12. Asia Pacific Cancer Pain Market
12.1. Asia Pacific Cancer Pain Market
12.1.1. Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
12.1.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
12.1.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
12.2. Japan Cancer Pain Market
12.2.1. Japan Market Size and Forecast, 2021-2029 (USD Million)
12.2.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
12.2.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
12.3. China Cancer Pain Market
12.3.1. China Market Size and Forecast, 2021-2029 (USD Million)
12.3.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
12.3.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
12.4. India Cancer Pain Market
12.4.1. India Market Size and Forecast, 2021-2029 (USD Million)
12.4.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
12.4.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
12.5. South Korea Cancer Pain Market
12.5.1. South Korea Market Size and Forecast, 2021-2029 (USD Million)
12.5.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
12.5.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
12.5.1.3. Market Size and Forecast by Device, 2021-2029 (USD Million)
12.6. Australia Cancer Pain Market
12.6.1. Australia Market Size and Forecast, 2021-2029 (USD Million)
12.6.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
12.6.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
12.7. Rest of Asia Pacific Cancer Pain Market
12.7.1. Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
12.7.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
12.7.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
13. Latin America Cancer Pain Market
13.1. Latin America Cancer Pain Market
13.1.1. Latin America Market Size and Forecast, 2021-2029 (USD Million)
13.1.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
13.1.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
13.2. Brazil Cancer Pain Market
13.2.1. Brazil Market Size and Forecast, 2021-2029 (USD Million)
13.2.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
13.2.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
13.3. Mexico Cancer Pain Market
13.3.1. Mexico Market Size and Forecast, 2021-2029 (USD Million)
13.3.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
13.3.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
13.4. Argentina Cancer Pain Market
13.4.1. Argentina Market Size and Forecast, 2021-2029 (USD Million)
13.4.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
13.4.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
13.5. Rest of Latin America Cancer Pain Market
13.5.1. Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
13.5.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
13.5.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
14. MEA Cancer Pain Market
14.1. MEA Cancer Pain Market
14.1.1. MEA Market Size and Forecast, 2021-2029 (USD Million)
14.1.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
14.1.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
14.2. GCC Cancer Pain Market
14.2.1. GCC Market Size and Forecast, 2021-2029 (USD Million)
14.2.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
14.2.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
14.3. South Africa Cancer Pain Market
14.3.1. South Africa Market Size and Forecast, 2021-2029 (USD Million)
14.3.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
14.3.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
14.4. Rest of MEA Cancer Pain Market
14.4.1. Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
14.4.1.1. Market Size and Forecast by Disease Indication, 2021-2029 (USD Million)
14.4.1.2. Market Size and Forecast by Drug Type, 2021-2029 (USD Million)
15. Competitor Analysis
15.1. Market Share Analysis, 2021 & 2029
15.2. Competitive Mapping
15.3. Key Players Market Place Analysis
15.4. Major Recent Developments
16. Company Profiles
16.1. Mundipharma International Limited
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financials
16.1.4. Disease Indication Benchmarking
16.1.5. Recent Developments
16.2. Biodelivery Sciences International, Inc
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financials
16.2.4. Disease Indication Benchmarking
16.2.5. Recent Developments
16.3. Aoxing Pharmaceutical Company, Inc.
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financials
16.3.4. Disease Indication Benchmarking
16.3.5. Recent Developments
16.4. Ck Life Sciences (Wex Pharmaceuticals)
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financials
16.4.4. Disease Indication Benchmarking
16.4.5. Recent Developments
16.5. Daiichi Sankyo Co. Ltd.
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financials
16.5.4. Disease Indication Benchmarking
16.5.5. Recent Developments
16.6. Hisamitsu Pharmaceutical Co., Inc.
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financials
16.6.4. Disease Indication Benchmarking
16.6.5. Recent Developments
16.7. Orexo Ab
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financials
16.7.4. Disease Indication Benchmarking
16.7.5. Recent Developments
16.8. Pfizer Inc.
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financials
16.8.4. Disease Indication Benchmarking
16.8.5. Recent Developments
16.9. Grünenthal Pharma Gmbh & Co. Kg
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financials
16.9.4. Disease Indication Benchmarking
16.9.5. Recent Developments
16.10. Teva Pharmaceutical Industries Limited
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financials
16.10.4. Disease Indication Benchmarking
16.10.5. Recent Developments
16.11. Company 11
16.11.1. Company Snapshot
16.11.2. Company Overview
16.11.3. Financials
16.11.4. Disease Indication Benchmarking
16.11.5. Recent Developments
16.12. Company 12
16.12.1. Company Snapshot
16.12.2. Company Overview
16.12.3. Financials
16.12.4. Disease Indication Benchmarking
16.12.5. Recent Developments
16.13. Company 13
16.13.1. Company Snapshot
16.13.2. Company Overview
16.13.3. Financials
16.13.4. Disease Indication Benchmarking
16.13.5. Recent Developments
16.14. Company 14
16.14.1. Company Snapshot
16.14.2. Company Overview
16.14.3. Financials
16.14.4. Disease Indication Benchmarking
16.14.5. Recent Developments
16.15. Company 15
16.15.1. Company Snapshot
16.15.2. Company Overview
16.15.3. Financials
16.15.4. Disease Indication Benchmarking
16.15.5. Recent Developments
16.16. Others Prominent Players
17. Conclusion & Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Mundipharma International Limited
  • Biodelivery Sciences International Inc.
  • Aoxing Pharmaceutical Company Inc.
  • Ck Life Sciences (Wex Pharmaceuticals).
  • Daiichi Sankyo Co. Ltd.
  • Hisamitsu Pharmaceutical Co. Inc.
  • Orexo Ab
  • Pfizer Inc.
  • Grünenthal Pharma Gmbh & Co. Kg
  • Teva Pharmaceutical Industries Limited.